Compare McKesson Corporation (MCK) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Prospect Capital Corporation — how do they compare? McKesson Corporation trades at $825.15 (market cap $97.35B), while Prospect Capital Corporation trades at $2.19 (market cap $1.12B). The key difference: McKesson Corporation is far larger — about 86.9× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (22.42%). Which is the better fit depends on your goals.
| MCK | PSEC | |
|---|---|---|
Market Cap | $97.35B | $1.12B |
Sector | Health | Financials |
52-Week High | $995.69 | $3.47 |
52-Week Low | $659.01 | $2.15 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | 22.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
PSEC trades at $2.235, down 0.67% on the day, with a bearish technical signal and neutral oscillators. The stock shows a deeply discounted P/B ratio of 0.38 but alarming fundamentals, including a negative revenue of -$407M and a net income margin of -495.94% for 2025. Recent quarterly EPS has consistently beaten estimates, and the company maintains regular dividend payments. Analyst consensus is mixed, with 25% buy ratings but a majority hold recommendation.
The outlook for PSEC is highly speculative. The extreme discount to book value and high dividend yield present a potential value opportunity, but this is overshadowed by severe profitability issues and negative cash flow. Investment carries significant risk due to the company's inconsistent revenue history and bearish market sentiment, requiring careful consideration of the underlying asset quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
